Lupin Fires Back At Novartis In Lotrel Patent Spat

Law360, New York (November 5, 2007, 12:00 AM EST) -- Indian generics giant Lupin Ltd. filed counterclaims Monday in a suit over Lotrel, saying Novartis Corp. deceived the U.S. Patent and Trademark Office into issuing the patent to the billion-dollar hypertension drug.

According to the counterclaims Lupin filed in the Maryland district court suit, the patent covering the drug — U.S. Patent Number 6,162,802, which isn't set to expire until Dec. 19 — is invalid, but even if the court found otherwise, Lupin's own filing last year of an Abbreviated New Drug Application for the formulation...
To view the full article, register now.